NFKB1 and rheumatoid arthritis: Because MAPKs, NFκB, STAT3 and RORγt are key regulators in RA pathogenesis and Th17 differentiation, we investigated whether etanercept and adalimumab would exert immunomodulatory effects on Th17-polarized cells by regulating these mediators.